| Peer-Reviewed

Neurological and Hematological Recovery Following Copper Replacement in Severe Copper Deficiency-induced Myelopathy and Cytopenia

Received: 21 December 2020    Accepted: 29 December 2020    Published: 18 January 2021
Views:       Downloads:
Abstract

Background: Copper deficiency can lead to a severe myelopathy and cytopenia. The myelopathy can lead to inability to walk by paresis and deafferentation. The anemia can as well be severe with the need for blood transfusions. Beside innate reasons it occurs years after surgeries of the intestine and following disturbed resorption. It can also occur due to excessive intake of zinc that binds copper. An early diagnosis following copper substitution can lead to restitution. It can clinically be mistaken for a vitamin B12 deficiency. This circumstance can lead to a delayed treatment. Case: A 67 years old woman with severe gait disturbances, sensory ataxia was admitted to our hospital. She had the diagnosis of vitamin B12 deficiency. B12 was elevated and metabolites were in normal range. The electrophysiology showed a deafferentation of the legs. Objective: This case report provides detailed information about the course of diagnosis and the treatment of a severe copper deficiency with symptomatic myelopathy and cytopenia in an elderly woman. Methods: We performed a literature research with keywords “spinal cord disease, gait disturbances, elevated lactate in cerebrospinal fluid, anemia”. We did blood tests and CSF on a regular basis combined with clinical assessments and electrophysiology. Results: Serum copper was not detectable. CSF copper was reduced (8.7 µg/l, Ref.: 14.2-109 µg/l), CSF lactate was elevated (4.69 mmol/l, Ref.: 1.1-2.4 mmol/l). The patient had a cytopenia (Hb 6.6 g/dl, Ref.: 12-16 g/dl, MCV 130 fl, Ref.: 80-96 fl, leucocytes 2.3 103, Ref.: 4.3-10 103/µl). Vitamin B12 amounted to 891 pg/ml (Ref.: 191-663 pg/ml). The somatosensory evoked potential (SEP) study showed absent cortical responses after stimulation of the sural nerves bilaterally. Due to the diagnosis of a myelopathy and bone marrow dysfunction due to copper deficiency we substituted copper-histidine subcutaneously. This led to a marked improvement of symptoms, an increase of serum copper levels (141 µg/l), CSF copper levels (14.1 µg/l), hemoglobin (11.9 g/dl), leukocyte count (11.4 103/µl) and a normalization of CSF lactate. Conclusion: Elevated CSF lactate might be an indicator for treatable myelopathy due to copper deficiency in patients with afferent gait disturbances. A timely substitution can lead to a marked improvement of even severe symptoms.

Published in Clinical Neurology and Neuroscience (Volume 5, Issue 1)
DOI 10.11648/j.cnn.20210501.11
Page(s) 1-4
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Copper Deficiency, Anemia, Spinal Cord Disease, Gait Disturbances Elevated CSF Lactate, Hypocupremia

References
[1] C. L. Rohm, S. Acree, and L. Lovett, “Progressive myeloneuropathy with symptomatic anaemia,” BMJ Case Reports, vol. 12, no. 12, Dec. 2019, doi: 10.1136/bcr-2019-230025.
[2] N. and A. EFSA NDA Panel (EFSA Panel on Dietetic Products, “Scientific Opinion on Dietary Reference Values for copper,” EFSA Journal, vol. 13, no. 10, pp. 4253–51 pp, Oct. 2015, doi: 10.2903/j.efsa.2015.4253.
[3] N. Kumar, “Copper deficiency myelopathy (human swayback),” Mayo Clinic Proceedings, vol. 81, no. 10, pp. 1371–1384, 2006, doi: 10.4065/81.10.1371.
[4] L. v. Puchkova, M. Broggini, E. v. Polishchuk, E. Y. Ilyechova, and R. S. Polishchuk, “Silver Ions as a Tool for Understanding Different Aspects of Copper Metabolism,” Nutrients, vol. 11, no. 6, Jun. 2019, doi: 10.3390/nu11061364.
[5] B. Schleper Hans Joerg Stuerenburg, B. Schleper, and H. J. Stuerenburg, “Copper deficiency-associated myelopathy in a 46-year-old woman,” J Neurol, vol. 248, pp. 705–706, 2001.
[6] A. A. Gabreyes, H. N. Abbasi, K. P. Forbes, G. Mcquaker, A. Duncan, and I. Morrison, “Hypocupremia associated cytopenia and myelopathy: A national retrospective review,” European Journal of Haematology, vol. 90, no. 1. pp. 1–9, Jan. 2013, doi: 10.1111/ejh.12020.
[7] X. Feng Wang and M. S. Cynader, “Pyruvate Released by Astrocytes Protects Neurons from Copper-Catalyzed Cysteine Neurotoxicity,” 2001.
[8] T. Hoppe-Tichy, M. Lorke, T. Hoppe-Tichy, T. H. Nguyen, and B. W. Hentze, “Kupferhistidin-Lösung zur Behandlung von Menkes’ Kinky Hair Syndrom: Herstellung und Stabilität,” Pharmazie, vol. 60, pp. 205–207, 2005, [Online]. Available: https://www.researchgate.net/publication/233516212.
[9] A. W. Zimmerman, J.-M. Matthieu, R. H. Quarles, R. O. Brady, and J. M. Hsu, “Hypomyelination in Copper-Deficient Rats Prenatal and Postnatal Copper Replacement,” Archives of Neurology, vol. 33, no. 2, pp. 111–119, 1976, [Online]. Available: http://archneur.jamanetwork.com/.
[10] Z. Tümer and L. B. Møller, “Menkes disease,” European Journal of Human Genetics, vol. 18, no. 5, pp. 511–518, May 2010, doi: 10.1038/ejhg.2009.187.
[11] R. A. Wapnir, “Copper absorption and bioavailability,” The American Journal of Clinical Nutrition, vol. 67, no. 5 Suppl, pp. 1054S-1060S, 1998.
[12] G. Ranucci, F. di Dato, M. I. Spagnuolo, P. Vajro, and R. Iorio, “Zinc monotherapy is effective in Wilson’s disease patients with mild liver disease diagnosed in childhood: A retrospective study,” Orphanet Journal of Rare Diseases, vol. 9, no. 1, Mar. 2014, doi: 10.1186/1750-1172-9-41.
[13] M. Magner et al., “Elevated CSF-lactate is a reliable marker of mitochondrial disorders in children even after brief seizures,” European Journal of Paediatric Neurology, vol. 15, no. 2, pp. 101–108, Mar. 2011, doi: 10.1016/j.ejpn.2010.10.001.
[14] W. W. Wainio, C. vander Wende, and N. F. Shimp, “Copper in Cytochrome c Oxidase,” THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 234, no. 9, 1959, Accessed: Nov. 01, 2020. [Online].
[15] S. Nargund, J. Qiu, and C. T. Goudar, “Elucidating the role of copper in CHO cell energy metabolism using 13C metabolic flux analysis,” Biotechnology Progress, vol. 31, no. 5, pp. 1179–1186, Sep. 2015, doi: 10.1002/btpr.2131.
Cite This Article
  • APA Style

    Christoph Roland Seifert, Ieva Didrihsone, Christian Isensee. (2021). Neurological and Hematological Recovery Following Copper Replacement in Severe Copper Deficiency-induced Myelopathy and Cytopenia. Clinical Neurology and Neuroscience, 5(1), 1-4. https://doi.org/10.11648/j.cnn.20210501.11

    Copy | Download

    ACS Style

    Christoph Roland Seifert; Ieva Didrihsone; Christian Isensee. Neurological and Hematological Recovery Following Copper Replacement in Severe Copper Deficiency-induced Myelopathy and Cytopenia. Clin. Neurol. Neurosci. 2021, 5(1), 1-4. doi: 10.11648/j.cnn.20210501.11

    Copy | Download

    AMA Style

    Christoph Roland Seifert, Ieva Didrihsone, Christian Isensee. Neurological and Hematological Recovery Following Copper Replacement in Severe Copper Deficiency-induced Myelopathy and Cytopenia. Clin Neurol Neurosci. 2021;5(1):1-4. doi: 10.11648/j.cnn.20210501.11

    Copy | Download

  • @article{10.11648/j.cnn.20210501.11,
      author = {Christoph Roland Seifert and Ieva Didrihsone and Christian Isensee},
      title = {Neurological and Hematological Recovery Following Copper Replacement in Severe Copper Deficiency-induced Myelopathy and Cytopenia},
      journal = {Clinical Neurology and Neuroscience},
      volume = {5},
      number = {1},
      pages = {1-4},
      doi = {10.11648/j.cnn.20210501.11},
      url = {https://doi.org/10.11648/j.cnn.20210501.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cnn.20210501.11},
      abstract = {Background: Copper deficiency can lead to a severe myelopathy and cytopenia. The myelopathy can lead to inability to walk by paresis and deafferentation. The anemia can as well be severe with the need for blood transfusions. Beside innate reasons it occurs years after surgeries of the intestine and following disturbed resorption. It can also occur due to excessive intake of zinc that binds copper. An early diagnosis following copper substitution can lead to restitution. It can clinically be mistaken for a vitamin B12 deficiency. This circumstance can lead to a delayed treatment. Case: A 67 years old woman with severe gait disturbances, sensory ataxia was admitted to our hospital. She had the diagnosis of vitamin B12 deficiency. B12 was elevated and metabolites were in normal range. The electrophysiology showed a deafferentation of the legs. Objective: This case report provides detailed information about the course of diagnosis and the treatment of a severe copper deficiency with symptomatic myelopathy and cytopenia in an elderly woman. Methods: We performed a literature research with keywords “spinal cord disease, gait disturbances, elevated lactate in cerebrospinal fluid, anemia”. We did blood tests and CSF on a regular basis combined with clinical assessments and electrophysiology. Results: Serum copper was not detectable. CSF copper was reduced (8.7 µg/l, Ref.: 14.2-109 µg/l), CSF lactate was elevated (4.69 mmol/l, Ref.: 1.1-2.4 mmol/l). The patient had a cytopenia (Hb 6.6 g/dl, Ref.: 12-16 g/dl, MCV 130 fl, Ref.: 80-96 fl, leucocytes 2.3 103, Ref.: 4.3-10 103/µl). Vitamin B12 amounted to 891 pg/ml (Ref.: 191-663 pg/ml). The somatosensory evoked potential (SEP) study showed absent cortical responses after stimulation of the sural nerves bilaterally. Due to the diagnosis of a myelopathy and bone marrow dysfunction due to copper deficiency we substituted copper-histidine subcutaneously. This led to a marked improvement of symptoms, an increase of serum copper levels (141 µg/l), CSF copper levels (14.1 µg/l), hemoglobin (11.9 g/dl), leukocyte count (11.4 103/µl) and a normalization of CSF lactate. Conclusion: Elevated CSF lactate might be an indicator for treatable myelopathy due to copper deficiency in patients with afferent gait disturbances. A timely substitution can lead to a marked improvement of even severe symptoms.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Neurological and Hematological Recovery Following Copper Replacement in Severe Copper Deficiency-induced Myelopathy and Cytopenia
    AU  - Christoph Roland Seifert
    AU  - Ieva Didrihsone
    AU  - Christian Isensee
    Y1  - 2021/01/18
    PY  - 2021
    N1  - https://doi.org/10.11648/j.cnn.20210501.11
    DO  - 10.11648/j.cnn.20210501.11
    T2  - Clinical Neurology and Neuroscience
    JF  - Clinical Neurology and Neuroscience
    JO  - Clinical Neurology and Neuroscience
    SP  - 1
    EP  - 4
    PB  - Science Publishing Group
    SN  - 2578-8930
    UR  - https://doi.org/10.11648/j.cnn.20210501.11
    AB  - Background: Copper deficiency can lead to a severe myelopathy and cytopenia. The myelopathy can lead to inability to walk by paresis and deafferentation. The anemia can as well be severe with the need for blood transfusions. Beside innate reasons it occurs years after surgeries of the intestine and following disturbed resorption. It can also occur due to excessive intake of zinc that binds copper. An early diagnosis following copper substitution can lead to restitution. It can clinically be mistaken for a vitamin B12 deficiency. This circumstance can lead to a delayed treatment. Case: A 67 years old woman with severe gait disturbances, sensory ataxia was admitted to our hospital. She had the diagnosis of vitamin B12 deficiency. B12 was elevated and metabolites were in normal range. The electrophysiology showed a deafferentation of the legs. Objective: This case report provides detailed information about the course of diagnosis and the treatment of a severe copper deficiency with symptomatic myelopathy and cytopenia in an elderly woman. Methods: We performed a literature research with keywords “spinal cord disease, gait disturbances, elevated lactate in cerebrospinal fluid, anemia”. We did blood tests and CSF on a regular basis combined with clinical assessments and electrophysiology. Results: Serum copper was not detectable. CSF copper was reduced (8.7 µg/l, Ref.: 14.2-109 µg/l), CSF lactate was elevated (4.69 mmol/l, Ref.: 1.1-2.4 mmol/l). The patient had a cytopenia (Hb 6.6 g/dl, Ref.: 12-16 g/dl, MCV 130 fl, Ref.: 80-96 fl, leucocytes 2.3 103, Ref.: 4.3-10 103/µl). Vitamin B12 amounted to 891 pg/ml (Ref.: 191-663 pg/ml). The somatosensory evoked potential (SEP) study showed absent cortical responses after stimulation of the sural nerves bilaterally. Due to the diagnosis of a myelopathy and bone marrow dysfunction due to copper deficiency we substituted copper-histidine subcutaneously. This led to a marked improvement of symptoms, an increase of serum copper levels (141 µg/l), CSF copper levels (14.1 µg/l), hemoglobin (11.9 g/dl), leukocyte count (11.4 103/µl) and a normalization of CSF lactate. Conclusion: Elevated CSF lactate might be an indicator for treatable myelopathy due to copper deficiency in patients with afferent gait disturbances. A timely substitution can lead to a marked improvement of even severe symptoms.
    VL  - 5
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Department of Neurology, Hermann-Josef-Hospital, Academic Educational Hospital of the University of Aachen, Erkelenz, Germany

  • Department of Neurology, Hermann-Josef-Hospital, Academic Educational Hospital of the University of Aachen, Erkelenz, Germany

  • Department of Neurology, Hermann-Josef-Hospital, Academic Educational Hospital of the University of Aachen, Erkelenz, Germany

  • Sections